Quick Answer
Nautilus Biotechnology, Inc. reported Cash and Equivalents of $12.39 million for fiscal year 2025.
Nautilus Biotechnology, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $12.39M | -55.2% |
| 2024 | $27.65M | +42.5% |
| 2023 | $19.40M | -83.1% |
| 2022 | $114.52M | -38.3% |
| 2021 | $185.62M | +407.1% |
| 2020 | $36.61M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $23.88M | +441.5% | -30.7% |
| June 30, 2025 | $34.46M | +38.5% | +3.7% |
| March 31, 2025 | $33.24M | +29.2% | +20.2% |
| December 31, 2024 | $27.65M | +42.5% | +527.0% |
| September 30, 2024 | $4.41M | -94.1% | -82.3% |
| June 30, 2024 | $24.89M | -65.5% | -3.3% |
| March 31, 2024 | $25.73M | -70.9% | +32.6% |
| December 31, 2023 | $19.40M | -83.1% | -73.8% |
- Nautilus Biotechnology, Inc. showed a decrease of -55.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Nautilus Biotechnology, Inc.’s cash and equivalents has declined by 66.2% (from $36.61 million to $12.39 million).
- The most recent figure is from Nautilus Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: